
THE Department of Health (DoH) announced last April 8 that it has “adopted the recommendation of the Food and Drug Administration (FDA) to temporarily suspend the use of AstraZeneca vaccines for individuals aged below 60-years-old, following recent reports of rare cases of blood clots with low platelets detected in some individuals inoculated with the vaccine.”
This action followed the April 7 issuance by the COVID-19 subcommittee of the World Health Organization (WHO) Global Advisory Committee on Vaccine Safety (GACVS).
It is important to know, understand, and appreciate the salient points of the WHO and DOH issuances, especially at this time that the rollout of COVID-19 vaccines has begun and there are millions of Filipinos waiting for their turn to be immunized while the strictest quarantine measures are being enforced.
First, this is a temporary pause, out of an abundance of caution, while the GACVS and other similar scientific bodies continue their studies on results of the use of AstraZeneca vaccines.
